Supplementary Table 6.
Comparison of Response Between Different C-P Classes in Cirrhotic Patients and Between Decompensated Patients With l and LT Recipients After Second SARS-CoV-2 Vaccination
| C-P class |
||||
|---|---|---|---|---|
| A (n = 16), median (IQR) | B (n = 18), median (IQR) | C (n = 14), median (IQR) | P | |
| Anti-S trimer titer, BAU/mL | 1890 (925–2105) | 1915 (668–5205) | 1870 (1358–3155) | .923 |
| Anti-S RBD titer, U/mL | 4124 (1542–6456) | 2951 (786–10307) | 4134 (2645–7849) | .576 |
| IFN-γ release titer, mIU/mL | 56 (9–396) | 252 (119–386) | 189 (64–286) | .423 |
| Patients with decompensated LC vs LT recipients |
|||||
|---|---|---|---|---|---|
| CP B+C (n = 34), median(IQR) | TIPS (n = 9), median(IQR) | LT (n = 82), median(IQR) | CP B+C vs LT | TIPS vs LT | |
| Anti-S trimer titer, BAU/mL | 1870 (1044–4350) | 1910 (1053–3990) | 163 (12–1060) | < .001 | .001 |
| Anti-S RBD titer, U/mL | 3812 (1128–9230) | 3693 (2186–4966) | 154 (1–1723) | < .001 | .002 |
| IFN-γ release titer, mIU/mL | 212 (93–359) | 168 (66–4532) | 49 (10–275) | .040 | .176 |
Note: Boldface P values indicate statistical significance.
Anti-S RBD, anti-SARS-CoV-2 antibodies in Roche Elecsys immunoassay; anti-S trimer, anti-SARS-CoV-2 antibodies in DiaSorin LIAISON immunoassay; BAU, binding antibody units; CP, Child-Pugh class; IFN-γ, interferon gamma; IQR, interquartile range; LC, liver cirrhosis patients; LT, liver transplant recipients; RBD, receptor binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; TIPS, transjugular intrahepatic portosystemic stent-shunt.